Education
About Us
Working with TipRanks
Follow Us
REPRO-MED Systems (KRMD)
NASDAQ:KRMD
KRMD Analyst Ratings
Moderate Buy
3 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
KRMD Stock 12 Month Forecast
Average Price Target
$4.88
▲(18.45% Upside)
| Highest Price Target$6.00 | Average Price Target$4.88 | Lowest Price Target$4.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$4→$4.5
Hold
9.22%
Upside
Reiterated
08/14/25
Canaccord Genuity
$5
Buy
21.36%
Upside
Reiterated
08/13/25
Strategic Growth and Innovation Drive Buy Rating for REPRO-MED SystemsBottom line: We hosted KORU Growth Conference. Overall, we continue to believe that the pieces are in place for ongoing momentum given the traction it is gaining OUS along with core SCIg market strength domestically and KRMD's ability to grow above it via new patient starts and share gains. Additionally, innovation is alive and well including multiple expected 510(K) submissions in 2025 and 2026 across its core platform and Novel Therapies. Its pipeline now includes two independent drug label additions (Iron Chelation and Antibiotics) that KRMD believes represent over 1M annual infusions in total, similar to the TAM for oncology infusions for which KRMD is currently undergoing a pilot program in the U.S.
Lake Street
$6
Buy
45.63%
Upside
Reiterated
08/07/25
Piper Sandler
$3.5→$4
Hold
-2.91%
Downside
Reiterated
08/07/25
Craig-Hallum
―
Buy
―
Reiterated
08/04/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$4→$4.5
Hold
9.22%
Upside
Reiterated
08/14/25
Canaccord Genuity
$5
Buy
21.36%
Upside
Reiterated
08/13/25
Strategic Growth and Innovation Drive Buy Rating for REPRO-MED SystemsBottom line: We hosted KORU Growth Conference. Overall, we continue to believe that the pieces are in place for ongoing momentum given the traction it is gaining OUS along with core SCIg market strength domestically and KRMD's ability to grow above it via new patient starts and share gains. Additionally, innovation is alive and well including multiple expected 510(K) submissions in 2025 and 2026 across its core platform and Novel Therapies. Its pipeline now includes two independent drug label additions (Iron Chelation and Antibiotics) that KRMD believes represent over 1M annual infusions in total, similar to the TAM for oncology infusions for which KRMD is currently undergoing a pilot program in the U.S.
Lake Street
$6
Buy
45.63%
Upside
Reiterated
08/07/25
Piper Sandler
$3.5→$4
Hold
-2.91%
Downside
Reiterated
08/07/25
Craig-Hallum
―
Buy
―
Reiterated
08/04/25
Best Analysts Covering REPRO-MED Systems
1 Month
xxx
Success Rate
8/15 ratings generated profit
Average Return
+4.96%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of +4.96% per trade.
3 Months
xxx
Success Rate
10/15 ratings generated profit
Average Return
+8.19%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +8.19% per trade.
1 Year
Success Rate
13/15 ratings generated profit
Average Return
+35.41%
reiterated a buy rating 9 days ago
Copying Frank Takkinen's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +35.41% per trade.
2 Years
xxx
Success Rate
14/15 ratings generated profit
Average Return
+56.74%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 93.33% of your transactions generating a profit, with an average return of +56.74% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KRMD Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
5
7
3
2
2
Buy
5
4
3
4
4
Hold
6
12
12
14
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
23
18
20
18
Each month's total comprises the sum of three months' worth of ratings.
KRMD Financial Forecast
KRMD Stock Forecast FAQ
What is KRMD’s average 12-month price target, according to analysts?
Based on analyst ratings, REPRO-MED Systems’s 12-month average price target is 4.88.
What is KRMD’s upside potential, based on the analysts’ average price target?
REPRO-MED Systems has 18.45% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KRMD a Buy, Sell or Hold?
REPRO-MED Systems has a consensus rating of Moderate Buy which is based on 3 buy ratings, 2 hold ratings and 0 sell ratings.
What is REPRO-MED Systems’s price target?
The average price target for REPRO-MED Systems is 4.88. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $6.00 ,the lowest forecast is $4.00. The average price target represents 18.45% Increase from the current price of $4.12.
The highest analyst price target is $6.00 ,the lowest forecast is $4.00. The average price target represents 18.45% Increase from the current price of $4.12.
What do analysts say about REPRO-MED Systems?
REPRO-MED Systems’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of KRMD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.